Hillhouse Capital
Hillhouse builds businesses that stand the test of time
Posted in Updates on
Wuxi Biologics, a leading provider of services for the discovery, development and manufacturing of biologics, raised $510 million in its Hong Kong IPO on June 12, 2017. The company is one of four business entities that emerged from the privatization of Wuxi Pharma, which was led by Hillhouse Capital and completed in December of 2015.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.